期刊文献+

门冬氨酸鸟氨酸联合纳洛酮治疗急性肝性脑病的临床疗效观察 被引量:15

The clinical effect of Ornithine Aspartate combined with naloxone in treatment of acute hepatic encephalopathy
暂未订购
导出
摘要 目的观察门冬氨酸鸟氨酸联合纳洛酮治疗急性肝性脑病的临床疗效。方法选取北京市第六医院2010年-2012年诊治的60例急性肝性脑病患者,随机分为门冬氨酸鸟氨酸治疗组(对照A组)15例、纳洛酮治疗组(对照B组)15例和门冬氨酸鸟氨酸联合纳洛酮治疗组(实验组)30例。各组均治疗7 d,对其治疗前后血氨浓度、肝功能(AST、TBIL)水平进行评价和比较,同时比较各组患者的临床疗效。结果治疗后对照A组和对照B组患者与实验组患者相比,其血氨及AST、TBIL水平差异均有统计学意义(P<0.05),且实验组显效率及总有效率(63.33%,90.00%)明显高于对照组(33.33%,63.33%),差异具有统计学意义(P<0.05)。结论门冬氨酸鸟氨酸联合纳洛酮治疗急性肝性脑病可以有效改善患者临床症状,提高临床疗效。 Objective To observe the clinical effect of Ornithine Aspartate combined with naloxone in treatment of acute hepatic encephalopathy.Methods Sixty cases of acute hepatic encephalopathy were selected in the Sixth Hospital of Beijing from 2010 to 2012,and randomly divided into Ornithine Aspartate treatment group (control group A,15 cases),Naloxone treatment group (control group B,15 cases) and Ornithine Aspartate combined naloxone treatment group (experimental group)with 30 cases.The changes of concentrations of plasma ammonium and total bilirubin (AST),aspartate transamlnase (TBIL) after 7 days treatment were compared,and the clinical effect in each group was compared.Results After 7 days treatment,the concentrations of plasma ammonium,AST,TBIL of experimental group were significant difference compared with control group A and control group B (P < 0.05),and the efficiency and total effective rate of experimental group (63.33%,90.00%) was significantly higher than those of control group (33.33%,63.33%) (P < 0.05).Conclusion Ornithine Aspartate combined with naloxone in treatment of acute hepatic encephalopathy can effectively ameliorate the clinical symptoms,and improve the clinical curative effect.
作者 苑林
出处 《胃肠病学和肝病学杂志》 CAS 2014年第7期825-827,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 门冬氨酸鸟氨酸 纳洛酮 急性肝性脑病 Ornithine Aspartate Naloxone Acute hepatic encephalopathy
  • 相关文献

参考文献9

二级参考文献12

  • 1陈合民.鸟氨酸—天门冬氨酸联合乳果糖治疗肝性脑病疗效观察[J].实用肝脏病杂志,2003,6(3):154-155. 被引量:12
  • 2陈孝治.瑞甘[J].中南药学,2004,2(4):254-255. 被引量:31
  • 3于中麟,钱林学.乳果糖在肝病治疗中的应用[J].中华内科杂志,1996,35(1):65-65. 被引量:37
  • 4叶主任.内科学.人民卫生出版社,2002:483.
  • 5Roger F, Butterworth H. Pathophysiology of hepatic eneephalopathy: anew look at ammonia. Metabolic Brain Disease, 2002,17 (4) : 221-227.
  • 6姚光弼.临床肝胆病学.上海:上海科技出版社,2004:281-296.
  • 7Kircheis G,Wettstein M,Dahl S, et al. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis, 2002,17 (4) : 453-462.
  • 8Kircheis G, Wettstein M, Dabl S, el al. Clinical emcacy of L -oralthine - L - aspartate in the management of hepatic encephalopathy [ J]. Metab Brain Dis,2002,17:453 - 462.
  • 9Roger F, Butterworth RF. Pathophysiology of hepatic encephalopathy:a new look at ammonia[ J]. Metabolic Brain Disease,2002,17 (4):221 -227.
  • 10陈灏珠.实用内科学[M]:第11版[M].北京:人民卫生出版,2001.707-713.

共引文献92

同被引文献121

  • 1陈孝治.瑞甘[J].中南药学,2004,2(4):254-255. 被引量:31
  • 2刘建生,傅极,张晓红,吴云林.肝性脑病血苯二氮和β-内啡肽变化及纳络酮治疗作用[J].医师进修杂志,2004,27(9):26-27. 被引量:12
  • 3陈晓辉,许松青,刘芳,江慧琳,林佩仪,熊旭明,李昭骥,陈敏生.纳洛酮对心肺复苏犬脑组织S100蛋白表达的影响[J].中华急诊医学杂志,2004,13(8):529-531. 被引量:13
  • 4叶任高,陆再英,钟南山.内科学[M].第7版,北京:人民卫生出版社,2010:463.
  • 5唐承薇.内科学.第7版.北京:人民卫生出版社,2008:463-468.
  • 6孙燕,周际星.临床肿瘤内科手册[M]第3版.北京:人民卫生出版社,1996:30.
  • 7陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 8陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:832-836.
  • 9Waghray A,Waghray N,Mullen K.Management of covert hepatic encephalopathy[J].J Clin Exp Hepatol,2015,5(Suppl 1):S75.
  • 10Matsushita N,Hashimoto E,Tokushige K,et al.Investigation of ornithine carbamoyltransferase as a biomarker of liver cirrhosis[J].Intern Med,2014,53(12):1249.

引证文献15

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部